NDA 213691, held by Pharmobedient. Clobetasol Propionate.
As of Nov 14, 2026, NDA 213691 (Impeklo), held by Pharmobedient, was first approved by FDA on May 19, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 19, 2020 | Original applicationNew formulation or manufacturer · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Impeklo0.05% · lotion;topical | Clobetasol Propionate | DiscontinuedReference drug |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
